Synthesis of Chemical Substances
ID: D-24-DC-0019RFIType: Sources Sought
Overview

Buyer

JUSTICE, DEPARTMENT OFDRUG ENFORCEMENT ADMINISTRATIONHEADQUATERSSPRINGFIELD, VA, 22152, USA

PSC

MEDICAL- LABORATORY TESTING (Q301)

Original Source

https://sam.gov/opp/9c257f83b1f24dcb9523d627754d675a/view
Timeline
    Description

    The Department of Justice, specifically the Drug Enforcement Administration (DEA), is seeking information and interest from qualified contractors for the synthesis of chemical substances, particularly psychoactive drugs, to enhance understanding and control of synthetic drugs. The procurement aims to identify manufacturers or researchers capable of producing controlled substances, including fentanyl and methamphetamine, while adhering to DEA regulations and providing comprehensive analytical reports on impurity profiles and yields. This initiative is crucial for informing regulatory actions and ensuring public safety against emerging drug threats. Interested parties should contact Darrell Goodwin at darrell.goodwin@dea.gov or Denise Scott at Denise.N.Scott@dea.gov for further details regarding this opportunity.

    Point(s) of Contact
    Darrell Goodwin
    darrell.goodwin@dea.gov
    Denise Scott
    Denise.N.Scott@dea.go
    Files
    Title
    Posted
    RFI Technical Questions.pdf
    The document outlines a Request for Information (RFI) regarding the capabilities of companies in synthetic drug manufacturing and analysis. It seeks qualified manufacturers or researchers registered with the DEA who can handle controlled substances (Schedules I-V). Key inquiries focus on the ability to produce starting materials, custom synthesis capabilities, and analytical methods for various classes of drugs, including synthetic opioids and cannabinoids. The RFI requests details about synthesis scales, retrosynthetic techniques, yield ratios, and analytical data generation including GC-MS and NMR results. Companies must describe their services in elucidating intermediates and impurities, determining reaction conditions, and generating analytical reports. Previous contract experience regarding detailed synthetic pathways and analytical outcomes is also required. The purpose of this document is to gather information on potential contractors capable of supporting federal efforts in drug synthesis and analysis, crucial for increasing understanding and control of synthetic drugs.
    SOW.pdf
    The Drug Enforcement Administration (DEA) seeks a contractor to synthesize various psychoactive substances and chemicals for evaluation to curb illicit drug manufacture. The requested synthesis involves creating controlled substances such as fentanyl and methamphetamine, employing specific precursors and methodologies. The contractor must hold DEA registration, demonstrating compliance with regulations surrounding controlled substances. Key tasks encompass providing lead time estimates, synthesizing substances within agreed timelines, and delivering comprehensive analytical reports detailing impurity profiles and yields. The contract spans a one-year base period, extendable by four additional years, allowing the DEA to better understand emerging drug threats and inform regulatory action. Bidders are evaluated on their technical approach, past performance, and pricing, with emphasis on quality assurance and familiarity with DEA requirements. The ultimate goal is to ensure public safety through informed regulation based on synthesized data and methodologies concerning new drug substances.
    Lifecycle
    Title
    Type
    Synthesis of Chemical Substances
    Currently viewing
    Sources Sought
    Similar Opportunities
    Drug Enforcement Administration (DEA) - Pre-Employment Processing & Hiring Center of Excellence
    Active
    Justice, Department Of
    The Drug Enforcement Administration (DEA) is seeking a contractor to establish and manage a Pre-Employment Processing & Hiring Center of Excellence to streamline the hiring process for various career fields, including Special Agents and Chemists. The contractor will be responsible for providing comprehensive pre-employment processing services, which may encompass site management, staffing, travel arrangements, and various assessments such as fingerprinting, psychological evaluations, and medical examinations. This initiative is crucial as the DEA anticipates approximately 900 job offers and 530 hires annually, aiming to enhance the efficiency of its hiring practices. Interested parties can submit informal replies or capability statements to Laura Over at laura.e.over@dea.gov, with no formal submissions currently required, as this is a new requirement without an incumbent contract.
    Destruction Transportation
    Active
    Justice, Department Of
    The Department of Justice, specifically the Drug Enforcement Administration (DEA), is seeking qualified vendors for the secure transportation of drug evidence as part of a Sources Sought notice. The objective is to transport approximately 20 tons of boxed, palletized drug evidence from DEA laboratories in California and Arizona to municipal waste combustors in Oklahoma or Indiana, either on a monthly or quarterly basis, due to the closure of such facilities in California starting January 2025. This procurement is critical for ensuring compliance with controlled substances laws and reflects the DEA's commitment to safe disposal practices in the fight against drug trafficking. Interested vendors must submit their capability statements and relevant information to Angel Barkley at angel.d.barkley@dea.gov by September 30, 2024, at 2:00 p.m. Eastern Standard Time, referencing “Destruction Transportation – DEA FORENSIC SCIENCES” in the subject line.
    Drug Enforcement Administration Polygraph Support Services
    Active
    Justice, Department Of
    The Drug Enforcement Administration (DEA) is seeking qualified contractors to provide polygraph support services as part of its hiring and employment processes. The contractor will be responsible for managing, scheduling, conducting, and reporting on 50 to 75 polygraph examinations monthly, ensuring compliance with federal regulations and DEA policies. This contract is crucial for maintaining the integrity and security of DEA personnel evaluations, with a performance period consisting of a 12-month base period and two optional 12-month extensions. Interested parties must submit their proposals, including a Technical Capability volume and a Price Quote volume, by September 30, 2023, and direct any inquiries to Contracting Officer Laura Over at laura.e.over@dea.gov or Nathan Wright at nathan.j.wright@dea.gov.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug substances. The primary objective is to ensure the Division of Preclinical Innovation (DPI) receives drug substances of adequate quality and quantity to support preclinical and Investigational New Drug (IND)-enabling studies, adhering to current Good Manufacturing Practice (cGMP) standards. This procurement is crucial for advancing therapeutics from preclinical stages to market readiness, emphasizing a multidisciplinary approach and compliance with regulatory requirements throughout the drug development pipeline. The Request for Proposals (RFP) is expected to be released on or about October 4, 2024, with contract awards anticipated in the second quarter of FY2025. Interested parties may contact Samson Shifaraw at samson.shifaraw@nih.gov for further information.
    Intramuscular Injectable Generic Analgesic Ketamine for use in an FDA Approved Emergency Use Authorization
    Active
    Dept Of Defense
    The Department of Defense, through the Army Medical Research Acquisition Activity, is seeking manufacturers for the procurement of intramuscular injectable generic analgesic ketamine intended for use under an FDA-approved Emergency Use Authorization (EUA) for battlefield injuries. The primary objective is to identify suppliers capable of providing ready-to-inject ketamine that meets specific criteria, including being an FDA-approved generic drug available in multidose vials and ready for immediate purchase, without any combination products. This initiative is crucial for enhancing pain management strategies within the military healthcare system, particularly for acute severe pain associated with battlefield injuries. Interested parties must submit a capabilities statement by October 7, 2024, addressing various topics such as FDA status and manufacturing capacity, with all submissions becoming government property. For further inquiries, contact Timothy Kelly at timothy.j.kelly169.civ@health.mil or call 301-619-7806.
    Outrider Receiver System
    Active
    Justice, Department Of
    The Drug Enforcement Administration (DEA) intends to negotiate a sole source procurement for an Outrider Receiver (ISR) system from Xone Technology, which specializes in providing precise geolocation capabilities for RF emissions. This procurement is critical for the DEA's operations, as the proprietary technology offered by Xone Technology is uniquely suited to meet the agency's specific requirements. The acquisition will be conducted under the FAR Part 13 "Simplified Acquisition Procedures," with a firm fixed-priced purchase order anticipated. Interested vendors may submit capability statements by September 26, 2024, at 10:00 AM EST, to Lisa Taylor at Lisa.Taylor2@dea.gov, as this notice does not constitute a request for competitive quotations.
    Dextroamphetamine/Amphetamine National Contract
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE Dextroamphetamine/Amphetamine National Contract is a procurement notice from the DEFENSE LOGISTICS AGENCY, specifically the DLA TROOP SUPPORT office. This notice falls under the category of MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES with a PSC code of 6515. The primary contact for this contract is Denise Taubman, who can be reached at DENISE.TAUBMAN@DLA.MIL or 215-737-8677. The notice describes an amendment, P00006, which incorporates additional clauses to the existing contract.
    Explosive and Drug Detection Equipment
    Active
    Dept Of Defense
    The Department of Defense, specifically the Department of the Air Force, is soliciting proposals for the procurement of explosive and drug detection equipment, including one desktop unit and two handheld devices. The desktop detector must be equivalent to the Bruker Detector Flex, capable of analyzing a wide range of drugs and explosives, while the handheld units should match the Bruker Detector Flex Roadrunner specifications, featuring similar detection capabilities and durability for various environmental conditions. This procurement aims to enhance detection capabilities at Keesler Air Force Base in Mississippi, supporting law enforcement and safety efforts. Interested parties, particularly women-owned small businesses, can direct inquiries to Eric Dismuke at eric.dismuke.1@us.af.mil or Kimberley L. Alvarez at kimberley.alvarez.1@us.af.mil, with proposals due as specified in the solicitation documents.
    Laptops
    Active
    Justice, Department Of
    The Department of Justice, specifically the Drug Enforcement Administration (DEA), is seeking quotes for the procurement of four Microsoft Surface Laptop Studio 2 units under solicitation number D-24-NI-0001. The laptops must meet specific technical requirements, including an Intel Core i7 processor, 32 GB of RAM, and a 1 TB SSD running Windows 11 Pro, to support the agency's operational needs. This procurement is critical for enhancing the DEA's technological capabilities while ensuring compliance with federal regulations and cybersecurity standards. Interested vendors must submit their quotes by September 19, 2024, at 11:00 am EST, and direct any questions to Jose Marin at jose.l.marin@dea.gov.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense (DoD) is soliciting quotations for pharmaceutical agents under the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at enhancing the Military Health System's pharmacy benefits. This procurement process is governed by 10 U.S.C. § 1074g and involves the evaluation of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on specific drug classes such as Oral CGRP migraine agents and Interleukin 17 and 23 targeted immunomodulatory biologics. Interested manufacturers must submit their quotes by September 19, 2024, following a pre-quotation teleconference scheduled for July 24, 2024, and can direct inquiries to primary contacts Stephanie Erpelding and Tracy Banks via their provided emails.